Abstract | BACKGROUND: METHODS: RESULTS: Fasting glucose (4.9 +/- 0.1 versus 5.2 +/- 0.2 mmol/l; P = 0.05) insulin concentrations (61.7 +/- 12.2 versus 83.9 +/- 12.2 pmol/l; P < 0.05), insulin : glucose ratio (12.6 +/- 1.7 versus 15.9 +/- 1.9 pmol/mmol; P < 0.05) and insulin resistance index by homeostasis model assessment (1.9 +/- 0.3 versus 2.8 +/- 0.5;P < 0.05) all increased significantly. During OGTT, 2 h glucose (5.1 +/- 0.4 versus 6.5 +/- 0.6 mmol/l; P < 0.05) and insulin levels (223.1 +/- 48.8 versus 390.3 +/- 108.8 pmol/l;P =0.05) also increased significantly. Insulin-mediated glucose disposal decreased significantly (10.4 +/- 1.4 versus 8.6 +/- 1.2 mg/kg x min per microU/ml insulin; 95% confidence interval 0.6--.0;P < 0.01). There was no significant change in lipoprotein, triglycerides or free fatty acid levels. There was a small loss of total body fat (15.8 +/- 1.4 versus 15.2 +/- 1.4 kg;P = 0.01) by X-ray absorptiometry without significant changes in weight, waist : hip ratio, and visceral or subcutaneous adipose tissue by computed tomography. CONCLUSIONS:
|
Authors | M A Noor, J C Lo, K Mulligan, J M Schwarz, R A Halvorsen, M Schambelan, C Grunfeld |
Journal | AIDS (London, England)
(AIDS)
Vol. 15
Issue 7
Pg. F11-8
(May 04 2001)
ISSN: 0269-9370 [Print] England |
PMID | 11399973
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Blood Glucose
- HIV Protease Inhibitors
- Insulin
- Lipids
- Lactic Acid
- Indinavir
|
Topics |
- Adult
- Aged
- Blood Glucose
(analysis)
- Glucose Tolerance Test
- HIV Protease Inhibitors
(administration & dosage, adverse effects, metabolism)
- HIV Seronegativity
(physiology)
- Health Status
- Humans
- Indinavir
(administration & dosage, adverse effects, metabolism)
- Insulin
(blood)
- Lactic Acid
(blood)
- Lipids
(blood)
- Male
- Middle Aged
|